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Abstract: Bordetella bronchiseptica is a respiratory animal pathogen that shows growing resistance to
commonly used antibiotics, which has necessitated the examination of new antimicrobials, including
bacteriophages. In this study, we examined the previously isolated and partially characterized B. bron-
chiseptica siphoviruses of the genus Vojvodinavirus (LK3, CN1, CN2, FP1 and MW2) for their ability to
inhibit bacterial growth and biofilm, and we examined other therapeutically important properties through
genomic analysis and lysogeny experiments. The phages inhibited bacterial growth at a low multiplicity
of infection (MOI = 0.001) of up to 85% and at MOI = 1 for >99%. Similarly, depending on the phages and
MOIs, biofilm formation inhibition ranged from 65 to 95%. The removal of biofilm by the phages was
less efficient but still considerably high (40–75%). Complete genomic sequencing of Bordetella phage LK3
(59,831 bp; G + C 64.01%; 79 ORFs) showed integrase and repressor protein presence, indicating phage
potential to lysogenize bacteria. Lysogeny experiments confirmed the presence of phage DNA in bacterial
DNA upon infection using PCR, which showed that the LK3 phage forms more or less stable lysogens
depending on the bacterial host. Bacterial infection with the LK3 phage enhanced biofilm production,
sheep blood hemolysis, flagellar motility, and beta-lactam resistance. The examined phages showed
considerable anti-B. bronchiseptica activity, but they are inappropriate for therapy because of their temperate
nature and lysogenic conversion of the host bacterium.
Keywords: Bordetella bronchiseptica; Vojvodinavirus; growth inhibition; biofilm; lysogeny
1. Introduction
Bordetella bronchiseptica is primarily a respiratory pathogen of domestic, wild, and lab-
oratory animals [1] and is considered to be the evolutionary progenitor of all species of the
Bordetella genus, including the well-known human pathogens B. pertussis and B. parapertus-
sis [2]. The prevalence of B. bronchiseptica infection is the highest in dogs, cats, swine, rabbits
and Guinea pigs, while bordetellosis is rarely documented in horses, monkeys, foxes, rats,
opossum, birds or other animals [3–5]. Infections caused by B. bronchiseptica can manifest
from almost asymptomatic to severe purulent pneumonia [6]. Moreover, B. bronchiseptica is
one of the main causative agents of a few highly contagious and economically significant
diseases, including kennel cough, atrophic rhinitis and upper respiratory tract disease
(snuffles) [7–9]. Although it is generally considered a zoonotic agent, B. bronchiseptica rarely
causes infection in humans, with the exception of immunocompromised individuals [10].
The vaccine for B. bronchiseptica, commonly used since 1970s, is unreliable as it does
not provide long-term immunity [11,12]. In addition, the increased degree of resistance to B.
bronchiseptica isolates against commonly used antibiotics, including β-lactams, macrolides
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and tetracyclines, has become a serious concern [13–15]. In the last few years, the use
of bacteriophages in the treatment of bacterial infections has gained the attention of the
scientific community [16–19]. Accordingly, bacteriophage therapy offers an alternative or
complementary strategy to conventional antimicrobials for more efficient B. bronchiseptica
control.
Only several B. bronchiseptica-specific phages have been isolated and characterized.
A few related B. bronchispetica phages from the Podoviridae family have been examined in
detail, and their genomic analysis indicated involvement in host lysogenic conversion [20].
Recently, phages from the Myoviridae and Podoviridae families that infect B. bronchiseptica
were described without showing evidence of lysogeny formation [21,22]. In addition,
we reported the first isolation of several phages from the Siphoviridae family that are
specific to B. bronchiseptica [23], but these were not characterized in detail. According to the
International Committee for Taxonomy of Viruses (ICTV) report (2019), these phages are
classified under the genus Vojvodinavirus [24]. They comprise four species—Bordetella virus
CN1 (with strains Bordetella phage CN1 and Bordetella phage LK3), Bordetella virus CN2,
Bordetella virus FP1 and Bordetella virus MW2. The partial genomic sequence of virus
CN1 showed similarity with Pseudomonas phages from the genus Yuavirus (40%), while
transmission electron microscopy, efficacy of plating and RFLP patterns demonstrated
high relatedness between examined siphoviruses [23]. Building on this work, we aimed
to determine if B. bronchiseptica-specific siphoviruses were appropriate for phage therapy.
We examined their potential to inhibit bacterial growth and biofilm formation and reduce
existing B. bronchiseptica biofilm. In addition, we used genomic analysis and conducted
lysogeny formation experiments to examine bacterial phenotypic properties after infection
with these phages.
2. Materials and Methods
2.1. Bacterial Strains
For estimation of phage lytic efficacy on biofilm formation and eradication of already
formed biofilm, the B. bronchiseptica ATCC 10580 strain was used. To examine lysogeny
formation, in addition to the reference strain, BbChiot and Bbr3416 animal strains were
used [25,26]. All bacteria were stored in Luria Bertani broth (LB) containing glycerol
(10% v/v) at −70 ◦C. For the experiments, they were inoculated in LB and incubated
overnight at 37 ◦C, if not stated otherwise.
2.2. Phages
Five B. bronchiseptica-specific siphoviruses (LK3, CN1, CN2, MW2 and FP1) previously
isolated from environmental samples and partially characterized, were examined in this
study [23]. All phages were propagated, precipitated in 10% PEG6000 and 1 M NaCl and
purified by CsCl discontinuous gradient ultracentrifugation (45,000× g, 6 h) [27]. The
obtained purified stocks were dialyzed and stored at 4 ◦C for all experiments.
2.3. Phage Genome Sequencing and Analysis
To determine the nature of phages (obligatory lytic or temperate) and other properties,
the genomes of five phages of the Vojvodinavirus genus (LK3, CN1, CN2, MW2 and FP1)
were sequenced and analysed. Their genomic DNA was obtained from the CsCl purified
phage suspensions after a standard phenol/chloroform extraction and ethanol precipitation,
followed by RNase treatment and DNA reprecipitation. The whole genome sequencing of
phages was performed using Illumina technology, while the de novo assembly of sequenced
fragments was carried out using CLC Genomics Workbench 6.5. ORFs (Open Reading
Frames) were predicted using GeneMarkS [28]. The analysis of each ORF was performed
using the BLAST algorithm, which enabled the comparison and identification of nucleotide
and protein sequences with the sequences deposited in database [29]. The presence of
tRNA in the phage genomes was analysed using tRNAscan-SE [30].
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2.4. Structural Protein Analysis
Phage LK3 virion structural proteins were concentrated from CsCl-purified samples
using methanol precipitation [31]. Extracted proteins were treated with Loading Buffer
(Tris-HCl, pH 9; 0.5 molL−1; SDS 4% w/v; glycerol 10% v/v; bromphenol blue 10% w/v;
2-merkaptoethanol 10% v/v) prior to heating at 95 ◦C for 10 min. The separation of
proteins and a standard (PierceTM Unstained Protein MW Marker, Thermo Fisher Scientific,
Vilnius, Lithuania) were performed using 10% w/v polyacrylamide gel and Eco-Medium
Electrophoresis System (Biometra, Göttingen, Germany) at 200 V for 100 min. SDS-PAGE
gel was stained using EZBlue Gel Staining Reagent (Sigma–Aldrich, St. Louis, MO, USA),
destained in distilled water and documented by BioDocAnalyze Transiluminator (Biometra,
Göttingen, Germany).
2.5. Phage Sensitivity to Environmental Factors
The effect of different physical and chemical factors on B. bronchiseptica phage (LK3,
CN2, MW2 and FP1) infectivity was examined, including temperature, pH, sodium chlo-
ride, and urea. In brief, after 30 min of 105 plaque-forming units (PFUs) mL−1 phage
exposure to different temperatures (4, 37, 45, 55, 65 and 75 ◦C), pH values (1.5, 3, 5, 7, 9
and 11), urea concentrations (0.5, 1, 3, 5, 7.5 and 10 M) and sodium chloride concentrations
(1.5, 3, 5, 7.5 and 10%), treated suspensions were mixed with soft top agar containing the
original host B. bronchiseptica ATCC 10580. The inoculated top agar was poured onto LB
agar and after overnight incubation at 37 ◦C, the plaques were counted. The experiment
was carried out in duplicate on two independent occasions. The results were presented as
the percentage of infected phages in the suspensions after treatment. The relation between
the starting phage PFUs and the obtained values were presented as mean ± SD.
2.6. In Vitro Inhibition of Bacterial Growth and Biofilm Formation by Phages
Three B. bronchiseptica siphoviruses (LK3, CN2 and FP1) were selected based on their
host range, RFLP profiles and whole genome-sequencing results Their lytic efficacy were
examined against the original hosts (B. bronchiseptica 10580) according to the method of
McLaughlin (2007) [32] modified by Knezevic and Petrovic (2008) [33]. In a sterile microtiter
of 96-well flat bottom plates, 50 µL of double strength LB were inoculated with a final
bacterial concentration of ~5 × 105 CFU mL−1 and an equal volume of 10-fold serial phage
dilutions in SM buffer were added (final volume 100 µL). The number of phages in wells
were between 1 × 102 and 1 × 106 PFU mL−1, and these corresponded to the multiplicity
of infection (MOI) in the range of 0.001–10. Controls containing only an inoculated medium
with sterile SM buffer (bacterial growth control), or SM buffer and uninoculated double-
strength LB (sterility control) were also included. After 24 h incubation at 37 ◦C, all wells
were amended with 0.1% 2,3,5-trifenil tetrazolium chloride (TTC) in a final concentration
of 200 µLmL−1. After additional 4 h incubation, TTC was reduced to red formazan in
wells with viable bacteria. Absorbance was measured by a Multiscan GO (Thermo Fisher
Scientific, Lithuania) microtiter plate reader at 540 nm. The absorbances were used to
estimate the lytic efficacy of the phages using previously described calculations [33,34].
The experiments were carried out in duplicate in a minimum of two repetitions, and the
results were presented as mean values of bacterial growth inhibition (%) with standard
deviation.
2.7. Phage Effect on B. bronchiseptica Biofilm Formation
The determination of phage effectiveness on biofilm formation was analysed by a
method developed by Knezevic and Petrovic, 2008 [33]. The effect of LK3, CN2 and FP1
phages was examined against the original host, B. bronchiseptica ATCC 10580. The content
of the well was identical to the one mentioned above in the lytic efficiency experiment.
Bacteria were grown in a LB medium, and after incubation every well was washed tree
times with PBS (pH 7.4), after which the plates were dried, and the biofilm was fixed for
15 min with 150 µL of methanol. Upon removal of the fixative, the plates were washed with
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tap water, air-dried, stained for 20 min with 150 µL of 0.4% crystal violet and finally the
excessive stain was removed with tap water. The plates were dried at 44 ◦C for 20 min. The
stain was diluted in glacial acetic acid (33%) for 20 min, and the absorbances in the wells
were measured using a Multiscan GO microtiter plate reader (Thermo Fisher Scientific,
Lithuania) at 595 nm. Every phage–bacteria combination was conducted in at least two
repetitions and two independent experiments. The results were presented graphically, and
calculations were the same for determining phage lytic efficacy.
2.8. Phage Effect on 24-h Old B. bronchiseptica Biofilm
The effect of LK3, CN2 and FP1 phages on already-formed biofilm was examined
after bacterial growth in an LB medium at 37 ◦C for 24 h. After incubation, all wells were
washed tree times with PBS (pH 7.4), and double-strength LB, and the same volume of
phage 10-fold dilutions were added to the wells. After additional incubation at 37 ◦C for
24 h, the plates were treated as described for biofilm formation inhibition.
2.9. Phage Genome Presence in Bacteria upon Infection
To infect bacteria with phage, B. bronchiseptica strains (ATCC 10580, Bbchiot and 3416),
which are sensitive to phage LK3, were incubated at 37 ◦C for 30 min at MOI 0.1, 1, 10 and
100. After incubation, single colonies were picked and cultivated on MacConkey agar and
further subcultivated the same way at least twice. To confirm phage infection, genomic
DNA were isolated from bacteria using a commercial GeneJET DNA purification kit
(Thermo Scientific, Lithuania). Prior to DNA extraction, the cells were washed three times
with PBS (NaCl 137.00 mmolL−1, KCl 2.70 mmolL−1 Na2HPO4 4.30 mmolL−1, KH2PO4
1.47 mmolL−1.) to remove potential phages that did not infect bacteria. A PCR was applied
for phage genome detection in bacteria, using two pairs of specific LK3 phage primers
(Bbr-targeting ribonucleotide–diphosphate reductase subunit alpha and Hem-targeting
virion structural protein) and a pair of B. bronchiseptica housekeeping gene recA primers as
a control (Table 1). Thermal cycling conditions were as follows: an initial cycle of 94 ◦C for
5 min followed by 35 cycles of 94 ◦C for 30 s, annealing at 55 ◦C for 30 s, and extension at
72 ◦C for 30 s, with a final 7 min extension at 72 ◦C. PCR products were analysed on 1%
agarose gel with ethidium bromide. A positive control was phage DNA and a negative
one was distilled water. The gels were documented using BioDocAnalyze Transiluminator
(Biometra, Germany). In addition to conventional PCR, restriction enzyme digestion was
used to confirm phage infection. Briefly, DNA of lysogenic and non-lysogenic bacteria
was treated with SalI fast-digest enzyme (Thermo Scientific, Lithuania) for 15 min at 37 ◦C,
followed by fragments separation on 1% of agarose gel. The SalI enzyme cuts bacterial DNA
producing great number of small fragments that appear on the gel as a smear. The phage
genome does not contain a SalI-specific sequence, so the enzyme does not digest the phage
DNA that appears on the gel as the highest clear single band. The DNA of non-lysogenic
bacteria treated with SalI and phage LK3 genomic DNA were used as controls.
Table 1. Primers used in the study.
Label of
Primer Sequence (5
′→3′) Expected Product (bp) Reference
Bbr-F TGA CTT CAT GGT TGC CGT TC 241
[23]Bbr-R TCG GGA GCG TGA TTT CAG TA
Hem-F ACG CCC GAA CCG TTA TTT GG 170 This study
Hem-R CAT TTC CCC GCA ACT CGA CA
RecA-F ATG GCG ACA ACG AGG TCG AA 263
[23]RecA-R CAG CAG GTC GGT CAG GTT GA
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2.10. Phenotypic Changes of lysogenic B. bronchiseptica
2.10.1. Biofilm Production of Lysogenic Bacteria
To determine the biofilm formation potential of lysogenic bacteria, the previously described
method by Stepanovic et al., 2000 was used [35]. Briefly, both lysogenic (ATCC10580+, Bbchiot+
and Bbr3416+) and non-lysogenic (ATCC10580, Bbchiot and Bbr3416) bacterial strains were
grown in LB medium over 48 h. After incubation, every strain was washed tree times with
sterile distilled water and the number of bacteria was adjusted to ~2 × 103, 2 × 105 and
2× 107 CFU mL−1. In two separated microtiter plates, 200 µL of bacterial suspension was
added, and both plates were placed at 37 ◦C; one plate was incubated for 24 h while the second
one was incubated for 48 h. The LB medium without bacteria was used as a negative control and
a Pseudomonas aeruginosa PAO1 reference strain was used as a positive control in the experiment.
After incubation, all wells, including controls, were washed three times with PBS (pH 7.4)
to remove planktonic cells that were not part of the biofilm. Formed biofilm was fixed with
150 µL of methanol for 15 min, after which the methanol was removed and the plates were
dried in an incubator at 44 ◦C for 20 min. Dried plates were stained with 0.4% crystal violet
solution for 15 min, after which the stain was removed by washing the plates with water. The
plates were then placed back into the incubator at 44 ◦C for 15–20 min to dry. After incubation,
150 µL of 33% acetic acid was added in each well to dissolve the stain from biofilm. Absorbance
was measured on Multiscan GO (Thermo Scientific, Lithuania) plate reader at 595 nm. The
experiment was carried out in triplicate and on three independent occasions. The results were
presented graphically, as mean value of absorbance with standard deviation.
2.10.2. Hemolytic Activity of Lysogenic Bacteria
To determine if there were a significant difference in hemolytic activity between
non-lysogenic and lysogenic bacterial strains, the method described by Janda and Abbott,
1993 [36] was used. In this experiment, a 1% erythrocyte solution was extracted from blood
(sheep, rat and cow) in 0.9% sodium chloride, after which the erythrocyte solution was
mixed with bacterial suspensions (~1.5 McFarland). The mixture was incubated at 37 ◦C
for 48 h after which the released hemoglobin was quantified using the microtiter plate
reader Multiscan GO (Thermo Fisher, Lithuania) at 540 nm. The 1% SDS solution was
used as a positive control, while 0.9% sodium chloride was used as a negative control. The
obtained values were analysed in STATISTICA 12.0, using the Student’s t-test to determine
if there were a statistically significant difference in the hemolysis of erythrocytes between
non-lysogenic and lysogenic strains.
2.10.3. Susceptibility of Lysogenic Bacteria to Antibiotics
The susceptibility of lysogenic bacteria antibiotics was determined by standard disk-
diffusion methods (Kirby–Bauer) and according to CLSI (2007). A total of 20 antibiotics
from different classes were used in the experiment: beta-lactams (ampicillin (10 µg), amoxi-
cillin (25 µg), amoxicillin/clavulanic acid (20/10 µg), cefalexin (30 µg), cefoxitin (30 µg),
ceftazidime (30 µg), cefotaxime (30 µg) and imipenem (10 µg)); aminoglycosides (amikacin
(30 µg), gentamicin (10 µg), streptomycin (10 µg), kanamycin (30 µg), tobramycin (10 µg),
netilmicin (30 µg) and neomycin (30 µg)], tetracycline [tetracycline (30 µg) and doxycy-
cline (30 µg)], phenicol [chloramphenicol (30 µg)); fluoroquinolones (ciprofloxacin (5 µg));
macrolides (aztreonam (30 µg)); and sulphonamides (sulfamethoxazole/trimethoprim
(23.75/1.25 µg)). Testing was done in two independent experiments and the values (i.e.,
diameters of inhibition zone by antibiotic) were analysed in STATISTICA 12.0 software
using the Student’s t-test to determine significant differences in sensitivities to antibiotics
between lysogenic and non-lysogenic B. bronchiseptica strains. Escherichia coli ATCC 25922
was used as a control. Results were expressed the average values of two experiments + SD.
2.10.4. Swimming and Twitching Motility of Lysogenic Bacteria
Flagellar motility, also known as swimming motility, was examined in lysogenic
bacteria using the method described by Kerns (2010) [37]. Briefly, bacteria were inoculated
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in the center of a semisolid LB Agar (0.3%) using a sterile needle. Both plates with lysogenic
and non-lysogenic bacteria were incubated at 37 ◦C for 48 h. Following incubation, the
diameter of the colony was measured, and the results presented as average + SE. The
flagella-independent form of motility, also known as twitching motility, was examined in
lysogenic bacteria using standard LB Agar. Lysogenic and non-lysogenic bacteria were
inoculated by a sterile needle in the center of the plate. Following incubation (37 ◦C for
48 h), the diameter of colony was measured in a Petri dish and medium interface and the
results were presented as average + SE. Both swimming and twitching motility experiments
were performed in duplicate in two independent occasions and the Pseudomonas aeruginosa
reference strain PAO1 was used as a control.
2.10.5. Fimbria Production
To better understand the phage role in B. bronchiseptica pathogenicity, the production
of fimbria in lysogenic bacteria was also examined. For this purpose, the adapted method
described by Jain and Chen (2007) was used [38]. Briefly, bacteria were cultured in LB Agar
containing 0.5% sodium chloride and subsequently incubated for 5 days at 26 and 37 ◦C.
After incubation, bacteria were suspended in 0.9% sodium chloride to ~1 × 109 CFU mL−1.
Bacterial suspension was then centrifuged (16,000 × g, 10 min) to obtain the pellet. A
solution of 0.002% Congo red was used to resuspend the bacterial pellet and the absorbance
was measured at 500 nm. The results were presented as a percentage of reduced Congo
red that was bound by fimbriae in comparison to the sterile solution without bacteria.
Escherichia coli ATCC 25922 was used as a control.
3. Results
3.1. Bordetella Phage LK3 Genome Properties
Complete genomic sequences of phages were deposited with GenBank under acces-
sion numbers KX961385 (LK3), KY000218 (MW2), KY000219 (CN2), KY000220 (FP1) and
KY000221 (CN1). The genome of LK3 phage consisted of double-stranded DNA with a
length of 59,831 bp and G + C composition of 64.01%, with no tRNA detected. Among the
total of 78 ORFs (GeneMark), 32 (40.5%) were identified as hypothetical proteins (Figure 1).
The LK3 genome also contains eight ORFs that shows no similarity with sequences
from the GenBank database. The predicted ORFs were roughly classified into three func-
tional regions: (i) nucleotide metabolism and DNA replication, (ii) host interaction, and
(iii) virion structure and packaging with lysis cassette (Figure 2). Putative genes encoding
repressor protein (ORF52) and integrase (ORF53) were detected in the genome, similar
to the integrase of Pseudomonas phage MP1412 at 99% and Pseudomonas phage PAE1
at 100%, respectively, which indicated the temperate nature of the phage. Nevertheless,
LK3 also possessed genes coding for DNA polymerase, primase and helicase, which are
involved in replication. A few genes involved in the host interaction were also detected,
such as diguanylate cyclase with GGDEF domain and an anti-restriction enzyme. The lytic
cassette of LK3 phage displayed similarity with other phages that infect Gram-negative
bacteria and consists of four overlapping genes: spanins, endolysin and holine. Analy-
sis of endolysin sequence revealed the lytic transglycosylase muralytic activity, globular
structure, and presence of signal peptide sequence.
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Figure 1. Genomic map of circularly permuted vB_BbrS_LK3 Bordetella phage dsDNA: the outer
ring illustrates the encoded genes/ORFs with putative functions indicated in the legend below the
circle; the central ring represents GC% content in the genome; the inner ring represents modules: (i)
nucleotide metabolism and DNA replication (black); (ii) host interaction module (white), and (iii)
particle structure and packaging module with lysis cassette (grey).
The whole genome phylogeny showed high sequence similarity among the five B.
bronchiseptica siphoviruses. (>88%) and relatively high homology to Pseudomonas Yua-like
siphoviruses (>40%); highest similarity was recorded with LKO4 (52.6%) and Yua (44.7%)
phages [24]. Based on these results, phages were selected for further characterisation which
included testing of sensitivity to different environmental factors (LK3, CN2, FP1 and MW2)
and their lytic efficacy against their original host (LK3, CN2, FP1).
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Figure 2. 1D SDS-PAGE of phage LK3 virion proteins; M—protein marker. Each band is designated
with appropriate ORF and the difference between the predicted and obtained proteins’ MW was less
than 5%.
3.2. Proteomic Characterization of LK3 Phage
Structural proteins of LK3 phage were analyzed by 1D sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and at least 9 protein bands of ~18–100 kDa
were detected, including major capsid proteins with a molecular weight of ~32.5 and
54.2 kDa (Figure 2). All bands corresponded to predicted structural proteins in silico, with
an acceptable error of molecular weight of less than 5% [39].
3.3. Phage Resistance to Environmental Factors
All phages were stable in a pH range of 3–11 for 30 min, and all lost infectivity at pH
1.5 (Figure 3A). Only phage FP1 was affected by 5% NaCl as this concentration reduced the
number of virions by more than 50%, while the other phages were resistant even to 10%
NaCl for 30 min (Figure 3B). The number of FP1 and MW2 virions was reduced by half at
65 ◦C for 30 min, while all phages were inactivated at 75 ◦C (Figure 3C). Similarly, 7.5 M of
urea reduced the number of FP1 and MW2 phages by half, while for phages CN2 and LK3
the same effect was obtained with 10 M of urea for 30 min (Figure 3D).
3.4. Phage Inhibition of Bacterial Growth and Biofilm Formation
The results of bacterial growth, biofilm inhibition and biofilm removal by LK3, CN2
and FP1 phages are shown in Figure 4.
All bacteriophages exhibited relatively high efficacy of lysis on original host B. bron-
chiseptica ATCC 10580. Even at the lowest MOI, inhibition of bacterial growth was consid-
erable (85%), with maximal inhibition reached at MOI 1 (>99%) (Figure 4A). The results of
biofilm inhibition (Figure 4B) and biofilm removal (Figure 4C) indicated that all phages
had a similar effect on B. bronchiseptica ATCC 10580 biofilm. At the lowest MOI, inhibition
of biofilm formation was 70%, while maximal inhibition was reached at MOI 1 and MOI 0.1
(>90%), in LK3/FP1 phages and the CN1 phage, respectively. However, phages showed
lower efficacy on 24 h-old biofilm compared to biofilm in the formation stage. The lowest
efficacy in biofilm reduction was at MOI 1 for LK3 (approx. 40%). Regardless of the results,
the efficacy of phages on existing biofilm was still considerably high, with the highest
efficacy reached by the same phage at MOI 0.01 (<80%).
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Figure 3. Effect of different pH (A), NaCl concentrations (B), temperatures (C) and urea concentrations (D) on the infectivity
of B. bronchiseptica phages CN2 (a), FP1 (b), LK3 (c) and MW2 (d).
Figure 4. Bacterial growth inhibition (A), inhibition of biofilm formation (B) and removal of B. bronchiseptica ATCC 10580
biofilm (C) by siphoviruses: LK3 (H), CN2 () and FP1 (•).
3.5. Confirmation of LK3 Infection and Stability of Lysogens
To confirm B. bronchiseptica infection with LK3 phage (ATCC 10580+, Bbchiot+ and
Bbr3416+), PCR was used for two pairs of phage-specific primers (Bbr and Hem). The
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expected products, 241 bp for Bbr and 170 bp for Hem primer pairs, were detected in the
genomic DNA of LK3 lysogenic bacterial strains (Figure 5A–C). Restriction digestion with
enzyme SalI additionally confirmed infection of B. bronchispetica strains with LK3 phage
(Figure 5D), as the enzyme cut bacterial DNA on a huge number of fragments, but the
phage DNA stayed intact and appeared on the gel as the highest uncut fragment. The
results of the experiments for stable phage genome persistence in bacteria indicated that
B. bronchiseptica LK3 phages formed unstable lysogens with the original host ATCC 10580
(Figure 5E). Namely, after the third subcultivation of the lysogenic strain, the expected
Hem PCR product was not detected, indicating absence of phage DNA in the strain. The
other two lysogenic strains, Bbchiot+ and Bbr3416+, showed greater stability, as the PCR
product was detected even after the sixth subcultivation, both in genomic and plasmid
DNA.
Figure 5. Confirmation of phage DNA presence in genomic DNA of bacterial strains ATCC 10580, BbChiot and Bbr3416
upon infection: (A) Quality control of bacterial DNA with Bbr-recA primers; (B) Infection confirmation with specific primers
Bbr-R and Bbr-F (product size 241 bp); (C) Infection confirmation with specific primers Hem-R and Hem-F (product size
170 bp); (D) Infection confirmation of bacterial strains ATCC 10580, BbChiot and Bbr3416 with restriction digestion with
enzyme SalI; phage DNA in lysogenic strain stayed intact.; (E) Presence of viral DNA in bacterial genomic DNA of strains
ATCC 10580, BbChiot and Bbr3416 during six successive transfers onto a new medium confirmed by primer pairs Hem
(I-VI); M—DNA ladder 100 bp; (C) a negative control; (+) lysogenic strain with phage.
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3.6. Lysogenic Conversion of B. bronchiseptica by LK3 Siphovirus
The potential of both non-lysogenic and lysogenic cells to form biofilm was examined us-
ing various starting bacterial numbers (~2× 103, 2× 105 and 2× 107 CFU mL−1) (Figure 6A–C).
Lysogenic strains showed increased adherent and aggregative growth in broth culture (Figure 6C
tube), with an exception for the LK3 lysogenic strain ATCC10580+ and Bbchiot+ at inoculum
~2× 103 CFU mL−1 after 24 h.
Figure 6. Biofilm production by non-lysogenic and lysogenic B. bronchiseptica strains after 24 and 48 h incubation. Starting
concentration of bacteria ~2 × 103 CFU mL−1 (A), ~2 × 105 (B) and 2 × 107 (C).
With the exception of these two cases, at all starting bacterial numbers lysogenic
strains showed statistically significant higher biofilm production after 24 h in compari-
son with non-lysogenic strains (p < 0.01). A statistically significant difference was also
determined between lysogenic and non-lysogenic strains of B. bronchiseptica after 48 h
incubation (p < 0.01) (Figure 5B). It is also interesting to note that some strains (Bbchiot+
and Bbr3416+) formed 2–4 times more biofilm compared to wild types. The results of
other phenotypic testing on lysogenic bacteria (ATCC 10580+) are summarized in Table 2.
Upon infection of the ATCC 10580 strain with phage LK3 (ATCC 10580+), an increase of
sheep blood hemolysis was noticed, while this activity against rat and cattle blood did not
change significantly. The phage increased flagellar motility of Bbchiot strain, while phage
infection had no effect on twitching motility and fimbria production. A change in antibiotic
susceptibility was also observed, most prominently against amoxicillin/clavulanic acid: as
an intermediate-sensitive strain, ATCC 10580 became resistant, and the sensitive Bbchiot
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strain became intermediately sensitive. A similar change from the intermediate-sensitive
strain Bbchiot to resistant was confirmed for ceftazidime. Although LK3 changed the
inhibition zone diameter around discs of doxycycline and sulfamethoxazole/trimethoprim,
the bacteria remained sensitive. Sensitivity to other antibiotics did not change significantly.
Table 2. Phenotypic changes of bacterial characteristics upon infection with Bordetella phage LK3.
Strains
Characteristics ATCC10580 ATCC10580+ Bbchiot Bbchiot+
Hemolysis
(%)
Sheep blood 14.3 ± 3.7 26 ± 0.28 * N.T. N.T.
Rat blood 47 ± 6.8 38.1 ± 6.1 N.T. N.T.
Cattle blood 66.95 ± 7 59.1 ± 12.02 N.T. N.T.
Motility
(mm)
Swimming 14.6 ± 0.7 14.4 ± 1.6 66.9 ± 2.5 78.2 ± 1.8
Twitching 4.0 ± 0.0 4.3 ± 0.2 5.0 ± 0.3 4.1 ± 0.2
Fimbria
production Congo-red reduction (%) 10.0 ± 2.1 11,8 ± 2 9.1 ± 1.3 8.5 ± 2.3
Susceptibility to
antibiotics 1 (mm)
Amoxicillin/clavulanic acid 15.8 ± 2.1 12.1 ± 0.9 * 18.8 ± 1.0 15.3 ± 0.9 *
Ceftazidime 17.3 ± 3.0 16.0 ± 2.0 20.0 ± 1.0 13.5 ± 0.5 *
Doxycycline 43.0 ± 1.2 38.3 ± 1.0 33.5 ± 1.7 35.9 ± 3.6
Sulfamethoxazole/Trimethoprim 25.5 ± 4.1 19.6 ± 1.1 0 0
1 Antimicrobials that do not cause change in inhibition diameter are not shown in the table; N.T. stands for not tested; Asterisks * indicate
significantly different values based on Student’s t-test (p ≤ 0.05).
4. Discussion
B. bronchiseptica siphoviruses had previously been isolated and morphologically char-
acterized, and their host range and RFLP pattern had been determined [23]. All phages
displayed mutually high similarity with certain variation, especially regarding RFLP pat-
tern and efficacy of plating. In this study their potential applicability as anti-Bordetella
agents and their usability in phage therapy were examined.
The in vitro lytic efficacy of B. bronchiseptica-specific siphoviruses showed up to 99%
total bacterial growth inhibition. The method applied can be considered as an estimation
of both the planktonic and biofilm phage effect [34,40,41]. The biofilm formation inhibition
indicated that B. bronchiseptica phages are highly efficient at biofilm prevention (up to
93% for CN1 phage), which was in accordance with the phage inhibition of total bacterial
growth; that is, the highest inhibition of both total bacterial growth and biofilm formation
by siphoviruses were at MOI 1. Since absolute inhibition of neither total bacterial growth
nor biofilm formation inhibition was achieved at MOI10, it is most likely that the phages
were temperate.
The 24 h-old B. bronchiseptica biofilm removal by phages was lower in comparison
to biofilm inhibition. The lower percentage of biofilm reduction by siphoviruses can be
explained by fact that biofilm is a complex microbial community in which gene expres-
sion and receptors for phages are quantitatively and qualitatively different from those in
planktonic cells [42]. The importance of pili in the initial phase of B. bronchiseptica biofilm
formation was highlighted by Irie et al. [43], and since the LK3 phage displayed DNA
sequence similarity with Pseudomonas phage Yua, which has pili as receptors [44], it is
very likely that LK3 phage also used these surface structures when adhering to the host cell.
Thus, in the complex matrix of biofilm, pili receptors are not available to phages as they are
in planktonic cells. Furthermore, bacteria in biofilm are less metabolically active, so phage
production is generally reduced as temperate phages integrate with the bacterial genome
rather than enter the lytic cycle [45]. Regardless, the lower efficacy of phages in biofilm
reduction compared to biofilm formation inhibition, Bordetella phage LK3 generally had
a satisfactory effect on biofilm prevention and removal. The relatively high reduction of
24 h-old biofilm can be explained by the fact that extracellular DNA (eDNA), as important
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component of biofilm matrix [46], occurred after 48 h of B. bronchiseptica incubation [47], so
the biofilm had not completely matured.
Taking into consideration that different factors can affect the efficacy of phage therapy,
primarily the multiplicity of infection (MOI) [48], in this study the lytic efficacy of LK3,
CN1 and FP1 phages were examined at different MOI (0.001–10) to determine at which
MOI value the best antibacterial effect was achieved. It is interesting that highest efficacy
was recorded at lower MOI values (0.001–0.1), indicating the potential integration of phage
with the bacterial genome [49]. Many authors such as Knezevic et al. [34], suggested that
MOI 10 is the most appropriate for a successful antibacterial phages effect because at this
MOI each bacterium is infected by at least one phage following the Poisson distribution.
However, when temperate phages are examined, the effect of different MOIs on phage lytic
activity is different [15,50]. One example is the lambda phage, for which phage integrase
activity directly depends on the concentration of cell proteases and MOI value: a low
concentration of protease or high MOI values enhance integrase activity, which promotes
phage entry into the lysogenic cycle. On the other hand, at a low MOI value, integrase
activity was reduced to a minimum and the phage did not integrate with the bacterial
genome but entered the lytic cycle [49]. Taking into account that the phage did not show
enhanced lytic properties at MOI 10, it seems that they were temperate, i.e., able to enter the
lysogenic cycle like a lambda phage. Good biofilm removal efficacy was recently observed
for a Yuavirus-related Pseudomonas phage Zc01, which was superior in comparison to
two Podoviridae and showed efficacy at a very low MOI, approx. 0.01 [51].
To consider phage properties further, the Bordetella phage LK3 genome was se-
quenced to reveal genes responsible for lysogenization. The LK3 phage displayed high
DNA-sequence similarity with a few Yua-related P. aeruginosas phages (MP1412, Yua and
LK04) [44,52], and possessed genes for integrase and repressor proteins. These findings
indicated that LK3 was capable of integrating into the host’s genome, further confirming its
temperate nature and, along with the previously confirmed pac site [23], indicating possible
phage involvement in transduction [53]. The genome of LK3 also has genes coding for
DNA polymerase, primase and helicase and others involved in replication. These genes
are part of the replisome, a multiprotein complex that dictates the coordinated synthesis of
both leading and lagging DNA [54] and increases replication efficacy [55]. The predicted
structural genes corresponded to the protein profile obtained by SDS-PAGE.
For genes involved in host interactions, the most interesting one detected in the LK3
phage genome, apart from integrase and repressor protein, was diguanylate-cyclase with
a GGDEF domain, which is involved in global secondary messenger synthesis (cGMP)
by controlling motility and biofilm formation in bacteria. This enzyme was previously
detected in Pseudomonas-specific phages from the genus Yuavirus and probably contributes
to bacteria properties, including those of B. bronchiseptica. The LK3 phage does not possess
a reverse transcriptase, which had previously been detected in the genome of the temperate
B. bronchiseptica phage from the family Podovirirdae and generates nucleotide diversity in
the mtd region, responsible for the specificity of receptor molecules [56]. It is worth high-
lighting the presence of the gene for anti-restriction protein (responsible for the interaction
with restriction enzymes and the tail-structural proteins ORF27 and ORF28) that contains
the F5/8 (discodin) domain of eukaryotic coagulation factor, which specifically binds to
phospholipids [57]. Proteins with this domain are not present in other Yua-related phages
and probably play a role in the interaction with bacterial cell membranes. Lysis cassettes of
LK3 phage consist of genes encoding pinholin, endolysin and spanin (Rz protein), which is
generally characteristic of phages that infect Gram-negative bacteria. An analysis of the
LK3 endolysin sequence confirmed the presence of a signal peptide sequence, supposed to
have a role in membrane integration, and that the existing pinholin contributed to the lytic
process by accelerating it and causing membrane depolarization [58,59]. The lysin can have
practical applications in bacterial growth control with further examination or modification.
Infection experiments confirmed that the LK3 phage genome can persist in the sen-
sitive strains (ATCC 10580, Bbchiot and Bbr3416) because the presence of phage DNA in
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the bacterial genomic DNA was confirmed. The stability of B. bronchiseptica LK3 lysogens
was tested through continuous subcultivation of lysogenic strains and infection persis-
tence, i.e., phage DNA presence. Taking into account that the Bbchiot and Bbr3416 strains
contained phage DNA after the sixth subcultivation, they formed stable lysogens. Unlike
them, the reference strain B. bronchiseptica ATCC 10580 lysogen did not show an equal
persistence of phage in the bacterial cell: phage DNA was not detected in bacteria after the
third subcultivation of the lysogenic strain, indicating that the LK3 phage formed unstable
lysognes of the reference strain. The Bordetella phage LK3 displayed a high degree of
morphological and genetic similarity with the Yua phage, which cannot form lysogeny.
Specifically, Ceyssens et al. [44] attempted unsuccessfully to confirm the presence of the
Yua phage in PAO1 colonies from blurry lysogenic strain plaques using PCR and RFLP.
The absence of lysogens was also observed for the related alpha-proteobacterium phage,
ϕJL001 [60,61]. The authors indicated that the Yua integrase requires specific physiological
conditions or an alternative host for stable lysogen establishment [44]. Other authors only
predicted the Yua-related phage’s temperate nature based on the presence of integrase
and repressor in the genome but did not try to check this property, which pertains to
phages PAE1 [62], S218 [63] and Ab18, 19 and 20 [64]. Thus, this is the first confirmation
that Yua-related siphoviruses can form lysogeny, which is not desirable from the point of
view of the application of phages in therapy. Considering that prophages almost always
influence the bacterial phenotype, the results of this study clearly indicated a potential role
for the B. bronchiseptica LK3 phage in lysogenic conversion [65].
After examining the LK3 lysogenic strains, it was confirmed that sheep blood hemol-
ysis and flagellar motility were elevated, confirming phage involvement in virulence.
Similarly, B. bronchiseptica infection with phage LK3 significantly reduced sensitivity to beta-
lactam antibiotics. More importantly, we showed that siphoviruses encode diguanylate-
cyclase with a GGDEF domain, a key initiator of biofilm formation in bacteria, and we
demonstrated hyperbiofilm production in lysogenic bacteria. These data clearly indicate
the possible role of siphoviruses in the biofilm formation of B. bronchiseptica, which is
thought to support bacterial survival and persistence in the mammalian respiratory tract.
The mechanisms of these changes, however, should be further examined, as well as the
effect of these phages to better understand the phage contribution to bacterial virulence.
Taking into consideration that B. bronchiseptica is known to modulate strongly both in-
nate and adaptive immune responses in mammals [66] and that temperate phages can
contribute to the attenuation of basic immune defenses such as phagocytosis [67], future
studies should also investigate the potential role of siphoviruses in the immunomodulation
and pathogenesis of B. bronchiseptica infections [68].
Since the phages are involved in the lysogenic conversion of B. bronchiseptica, their
susceptibility to environmental factors was also determined. The phages tolerate a range
of pH, high temperatures and concentrations of salt and urea, and the demonstrate the
ability to persist even in environments unfavorable to the host bacteria. It is well known
that among phages, members of family Siphoviridae possess the most stable virions [69].
Maintenance of infectivity at high temperatures (65 ◦C) is of great importance, as we have
shown here that these phages are involved in bacterial virulence, and pasteurization is not
a barrier to their transmission.
5. Conclusions
In summary, this is the first evidence of the antibacterial activity of B. bronchiseptica
bacteriophages. the first genomic analysis of a B. bronchiseptica-specific phage from the
family Siphoviridae and the first confirmation of lysogeny formation by Pseudomonas phage
Yua-related bacteriophages. The phages are not appropriate for phage therapy because of
their temperate nature despite the high total bacterial growth inhibition and anti-biofilm
effect. They affect bacterial biofilm production, hemolytic properties, motility and antibiotic
susceptibility, indicating involvement in lysogenic conversion. Furthermore, the phages
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are stable under unfavorable conditions for B. bronchiseptica, so they can persist in the
environment and lysogenize new hosts.
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